智通财经APP讯，艾迪康控股(09860)发布截至2025年6月30日止6个月中期业绩，该集团取得收益人民币12.71亿元(单位下同)，同比减少13.31%;母公司拥有人应占溢利2727.3万元，同比减少73.15%;每股盈利0.04元。
公司的总收入达12.7亿，同比下滑13.3%。尽管经济周期调整及政策变动给公司带来短期压力，但本公司的业务组合持续巩固其韧性，并支撑了多个板块的良好发展势头。
期内，共建业务收入同比增长30%，四年CAGR达48%，主要受益于多家大型三甲医院项目的成功落地。展望下半年，公司计划深化与领先医疗机构的战略合作，推动更多标杆性项目落地。
CRO业务收入同比增长18%。公司通过与国内外领先药企的深度合作，持续巩固糖尿病领域优势地位，在NASH领域取得强劲表现，并在实体瘤治疗领域实现创新突破，拓展全新业务版图。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.